Ghent University Academic Bibliography

Advanced

Evidence of protection against clinical and chronic hepatitis B infection 20 years after infant vaccination in a high endemicity region

Y Poovorawan, V Chongsrisawat, A Theamboonlers, Geert Leroux-Roels UGent, S Kuriyakose, M Leyssen and JM Jacquet (2011) JOURNAL OF VIRAL HEPATITIS. 18(5). p.369-375
abstract
Vaccination against hepatitis B virus (HBV) immediately after birth prevents neonatal infection by vertical transmission from HBV carrier mothers. There is an ongoing debate whether infant vaccination is sufficient to protect against infection when exposed to HBV later in life. We studied 222 Thai infants born to HBsAg -/+ and HBeAg -/+ mothers who were vaccinated with recombinant hepatitis B vaccine at 0-1-2-12 months of age. A subset of 100 subjects received a booster dose at age 5 years. Blood samples collected yearly for 20 years were examined for anti-HBs antibodies and serological markers of hepatitis B infection (anti-HBc, HBsAg, and in selected cases HBeAg, anti-HBe, HBV DNA). During the 20-year follow-up, no subject acquired new chronic HBV infection or clinical hepatitis B disease. During the first decade, possible subclinical breakthrough HBV infection (anti-HBc seroconversion) was only observed in subjects born to HBsAg +/HBeAg + mothers (6/49 [12.2%]). During the second decade, breakthrough HBV infections were detected in all groups (18/140 [12.8%]). Increases in anti-HBs concentrations that were unrelated to additional HBV vaccination or infection were detected in approximately 10% of subjects in each decade. Primary infant vaccination with a recombinant hepatitis B vaccine confers long-term protection against clinical disease and new chronic hepatitis B infection despite confirmed hepatitis B exposure. (http://www.clinicaltrials.gov NCT00240500 and NCT00456625).
Please use this url to cite or link to this publication:
author
organization
year
type
journalArticle (original)
publication status
published
subject
keyword
EXPANDED PROGRAM, VACCINES, hepatitis B, THAILAND, SEROPREVALENCE, IMMUNIZATION, CHILDREN, ANTIGEN-POSITIVE MOTHERS, LONG-TERM EFFICACY, TAIWAN, IMPACT, efficacy, vaccine
journal title
JOURNAL OF VIRAL HEPATITIS
J. Viral Hepatitis
volume
18
issue
5
pages
369 - 375
Web of Science type
Article
Web of Science id
000289251900008
JCR category
GASTROENTEROLOGY & HEPATOLOGY
JCR impact factor
4.088 (2011)
JCR rank
15/73 (2011)
JCR quartile
1 (2011)
ISSN
1352-0504
DOI
10.1111/j.1365-2893.2010.01312.x
language
English
UGent publication?
yes
classification
A1
copyright statement
I have transferred the copyright for this publication to the publisher
id
1231040
handle
http://hdl.handle.net/1854/LU-1231040
date created
2011-05-23 16:55:01
date last changed
2016-12-19 15:46:03
@article{1231040,
  abstract     = {Vaccination against hepatitis B virus (HBV) immediately after birth prevents neonatal infection by vertical transmission from HBV carrier mothers. There is an ongoing debate whether infant vaccination is sufficient to protect against infection when exposed to HBV later in life. We studied 222 Thai infants born to HBsAg -/+ and HBeAg -/+ mothers who were vaccinated with recombinant hepatitis B vaccine at 0-1-2-12 months of age. A subset of 100 subjects received a booster dose at age 5 years. Blood samples collected yearly for 20 years were examined for anti-HBs antibodies and serological markers of hepatitis B infection (anti-HBc, HBsAg, and in selected cases HBeAg, anti-HBe, HBV DNA). During the 20-year follow-up, no subject acquired new chronic HBV infection or clinical hepatitis B disease. During the first decade, possible subclinical breakthrough HBV infection (anti-HBc seroconversion) was only observed in subjects born to HBsAg +/HBeAg + mothers (6/49 [12.2\%]). During the second decade, breakthrough HBV infections were detected in all groups (18/140 [12.8\%]). Increases in anti-HBs concentrations that were unrelated to additional HBV vaccination or infection were detected in approximately 10\% of subjects in each decade. Primary infant vaccination with a recombinant hepatitis B vaccine confers long-term protection against clinical disease and new chronic hepatitis B infection despite confirmed hepatitis B exposure. (http://www.clinicaltrials.gov NCT00240500 and NCT00456625).},
  author       = {Poovorawan, Y and Chongsrisawat, V and Theamboonlers, A and Leroux-Roels, Geert and Kuriyakose, S and Leyssen, M and Jacquet, JM},
  issn         = {1352-0504},
  journal      = {JOURNAL OF VIRAL HEPATITIS},
  keyword      = {EXPANDED PROGRAM,VACCINES,hepatitis B,THAILAND,SEROPREVALENCE,IMMUNIZATION,CHILDREN,ANTIGEN-POSITIVE MOTHERS,LONG-TERM EFFICACY,TAIWAN,IMPACT,efficacy,vaccine},
  language     = {eng},
  number       = {5},
  pages        = {369--375},
  title        = {Evidence of protection against clinical and chronic hepatitis B infection 20 years after infant vaccination in a high endemicity region},
  url          = {http://dx.doi.org/10.1111/j.1365-2893.2010.01312.x},
  volume       = {18},
  year         = {2011},
}

Chicago
Poovorawan, Y, V Chongsrisawat, A Theamboonlers, Geert Leroux-Roels, S Kuriyakose, M Leyssen, and JM Jacquet. 2011. “Evidence of Protection Against Clinical and Chronic Hepatitis B Infection 20 Years After Infant Vaccination in a High Endemicity Region.” Journal of Viral Hepatitis 18 (5): 369–375.
APA
Poovorawan, Y, Chongsrisawat, V., Theamboonlers, A., Leroux-Roels, G., Kuriyakose, S., Leyssen, M., & Jacquet, J. (2011). Evidence of protection against clinical and chronic hepatitis B infection 20 years after infant vaccination in a high endemicity region. JOURNAL OF VIRAL HEPATITIS, 18(5), 369–375.
Vancouver
1.
Poovorawan Y, Chongsrisawat V, Theamboonlers A, Leroux-Roels G, Kuriyakose S, Leyssen M, et al. Evidence of protection against clinical and chronic hepatitis B infection 20 years after infant vaccination in a high endemicity region. JOURNAL OF VIRAL HEPATITIS. 2011;18(5):369–75.
MLA
Poovorawan, Y, V Chongsrisawat, A Theamboonlers, et al. “Evidence of Protection Against Clinical and Chronic Hepatitis B Infection 20 Years After Infant Vaccination in a High Endemicity Region.” JOURNAL OF VIRAL HEPATITIS 18.5 (2011): 369–375. Print.